Myasthenia gravis (MG) is a chronic autoimmune disease that causes partial or systemic skeletal muscle weakness and fatigue. Efgartigimod is an antibody fragment targeting the Fc receptor in newborns, which clears pathogenic immunoglobulin G antibodies through a unique mechanism. Efgartigimod is used to treat systemic myasthenia gravis safely and efficiently, which can significantly improve muscle strength and quality of life for patients. This article reviews pharmacological, clinical research, and safety of efgartigimod, in order to providing reference for its clinical treatment in systemic myasthenia gravis (gGM).